Evidence map›Paper›PMID 38833371›Full record

ArticleCell reports2024

Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity.

Prabhat K Purbey, Joowon Seo, Manash K Paul, Keisuke S Iwamoto, Allison E Daly, An-Chieh Feng, Ameya S Champhekar, Justin Langerman, Katie M Campbell, Dörthe Schaue and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Analysis of the Transcriptional Control ofAnimals : an open access journal from MDPI · 2025
    Article
  16. Review
  17. Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024
    Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Prabhat K PurbeyDepartment of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Electronic address: ppurbey@mednet.ucla.edu.
Joowon SeoDepartment of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Manash K PaulDepartment of Medicine, Division of Pulmonology and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Department of Radiation Biology and Toxicology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Keisuke S IwamotoDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Allison E DalyDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
An-Chieh FengDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Ameya S ChamphekarDepartment of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Justin LangermanDepartment of Biological Chemistry, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Katie M CampbellDepartment of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Dörthe SchaueDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
William H McBrideDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Steven M DubinettDepartment of Medicine, Division of Pulmonology and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Antoni RibasDepartment of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Stephen T SmaleDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Philip O ScumpiaDepartment of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. Electronic address: pscumpia@mednet.ucla.edu.

Funding

UCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHUTE, JOHN P, MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
Leveraging immune-fibroblast interactions for biomaterial induced skin regenerationR01AR079470 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCUMPIA, PHILIP · 2021 to 2025
$2.6M
Regulation of macrophage transcriptional networks by stress pathways in the skinK08AR066545 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCUMPIA, PHILIP · 2014 to 2018
$781k
Machine Learning and Reflectance Confocal Microscopy for Biopsy-free Virtual Histology of Squamous Skin NeoplasmsI01CX002194 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI SCUMPIA, PHILIP · 2022 to 2025
–
CSRD VA I01 CX002194NCI NIH HHS P01 CA244118NCI NIH HHS R35 CA197633NIAID NIH HHS U19 AI067769NIAMS NIH HHS K08 AR066545NIAMS NIH HHS R01 AR079470
6 · The paper itself

Abstract

Type I interferon (IFN-I) and IFN-γ foster antitumor immunity by facilitating T cell responses. Paradoxically, IFNs may promote T cell exhaustion by activating immune checkpoints. The downstream regulators of these disparate responses are incompletely understood. Here, we describe how interferon regulatory factor 1 (IRF1) orchestrates these opposing effects of IFNs. IRF1 expression in tumor cells blocks Toll-like receptor- and IFN-I-dependent host antitumor immunity by preventing interferon-stimulated gene (ISG) and effector programs in immune cells. In contrast, expression of IRF1 in the host is required for antitumor immunity. Mechanistically, IRF1 binds distinctly or together with STAT1 at promoters of immunosuppressive but not immunostimulatory ISGs in tumor cells. Overexpression of programmed cell death ligand 1 (PD-L1) in Irf1

Indexed as

Interferon Regulatory Factor-1AnimalsB7-H1 AntigenCell Line, TumorFemaleHumansImmunityMaleMiceMice, Inbred C57BLNeoplasmsSTAT1 Transcription FactorB7-H1 AntigenInterferon Regulatory Factor-1IRF1 protein, humanIrf1 protein, mouseSTAT1 Transcription Factorantitumor immunityCP: CancerCP: Immunologycytotoxic T lymphocytesimmune checkpoint blockadeimmune evasioninterferon signalingIRF1PD-L1 regulationscRNA-seqTLR signalingtranscription

Identifiers

PMID38833371
PMCPMC11315447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.